Eli Lilly initiates Phase 1 trial of oral IDH inhibitor LY3410738 in hematologic malignancies
Eli Lilly is conducting Phase 1 trial of LY3410738, targeting patients with IDH1 or IDH2 mutations in advanced hematologic malignancies.
Therapeutic Area
Therapeutic area intelligence for IDH Inhibition with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.